GB202102369D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB202102369D0
GB202102369D0 GBGB2102369.2A GB202102369A GB202102369D0 GB 202102369 D0 GB202102369 D0 GB 202102369D0 GB 202102369 A GB202102369 A GB 202102369A GB 202102369 D0 GB202102369 D0 GB 202102369D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2102369.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Priority to GBGB2102369.2A priority Critical patent/GB202102369D0/en
Publication of GB202102369D0 publication Critical patent/GB202102369D0/en
Priority to PCT/GB2022/050441 priority patent/WO2022175671A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2102369.2A 2021-02-19 2021-02-19 Treatment Ceased GB202102369D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2102369.2A GB202102369D0 (en) 2021-02-19 2021-02-19 Treatment
PCT/GB2022/050441 WO2022175671A1 (en) 2021-02-19 2022-02-18 Trifluoperazine for use in the treatment of neurobéastoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2102369.2A GB202102369D0 (en) 2021-02-19 2021-02-19 Treatment

Publications (1)

Publication Number Publication Date
GB202102369D0 true GB202102369D0 (en) 2021-04-07

Family

ID=75339205

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2102369.2A Ceased GB202102369D0 (en) 2021-02-19 2021-02-19 Treatment

Country Status (2)

Country Link
GB (1) GB202102369D0 (en)
WO (1) WO2022175671A1 (en)

Also Published As

Publication number Publication date
WO2022175671A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
GB202108224D0 (en) Treatment
GB202116743D0 (en) Treatment
GB202103122D0 (en) Treatment
GB202016058D0 (en) Therapeautic treatment
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202114373D0 (en) Treatment
GB202109815D0 (en) Treatment
GB202109812D0 (en) Treatment
GB202104666D0 (en) COVID-19 treatment
GB202104416D0 (en) Treatment reginmens
GB202103957D0 (en) Treatment
GB202102488D0 (en) Treatment
GB202102373D0 (en) Treatment
GB202102410D0 (en) Treatment
GB202102366D0 (en) Treatment
GB202102369D0 (en) Treatment
GB202101897D0 (en) Treatment
GB202101875D0 (en) Treatment
GB202101213D0 (en) Treatment
GB202101212D0 (en) Treatment
GB202101210D0 (en) Treatment
GB202101211D0 (en) Treatment
GB202100976D0 (en) Treatment
GB202020165D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)